Joshua Brumm

Josh serves as President and Chief Executive Officer at Dyne Therapeutics. He was previously COO and CFO of Kaleido Biosciences leading the company through its initial IPO and its Phase 2 programme development. While serving as COO and CFO at Versartis, Josh spearheaded the finance strategy, its IPO and successful first product partnership. His previous roles include: EVP of Finance (Pharmacyclics); CFO (Zeltiq Aesthetics) and investment banking positions at Citigroup Global Markets Inc, and Morgan Stanley. Over the course of his career, Josh has raised nearly $2 billion in capital. He holds a B.A. in Business Administration from the University of Notre Dame.